Reported 2 days ago
Insulet Corporation (PODD) has been rated as a strong buy by Canaccord Genuity, which raised its price target from $353 to $399. The firm slightly increased its 2025 revenue expectation from $2.627 billion to $2.639 billion and adjusted its 2026 revenue projection from $3.033 billion to $3.046 billion, also enhancing operating margins. However, earnings per share estimates were lowered from $6.09 to $5.74 due to revised net interest expense assumptions. Insulet is recognized as a leader in tubeless insulin pump technology.
Source: YAHOO